Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of coxsackievirus b3-induced viral myocarditis reduces myocardium inflammation
2011

IL-17 Antibody Treatment Reduces Heart Inflammation in Viral Myocarditis

Sample size: 32 publication 10 minutes Evidence: moderate

Author Information

Author(s): Fan Yang, Weifeng Wu, Yuluan Yan, Qing Kong, Yu Pang, Yanlan Huang

Primary Institution: Guangxi Cardiovascular Institute

Hypothesis

Does neutralizing IL-17 after the onset of viral myocarditis improve heart inflammation and survival rates in mice?

Conclusion

Neutralizing IL-17 with a monoclonal antibody after the onset of viral myocarditis reduces inflammation and improves survival rates in mice.

Supporting Evidence

  • The survival rate of IL-17mAb group mice was significantly improved compared to the isotype control and PBS groups.
  • IL-17mAb treatment reduced the severity of myocarditis as indicated by lower heart weight/body weight ratios and pathological scores.
  • IL-17mAb decreased circulating levels of IL-17 compared to control groups.

Takeaway

This study shows that giving a special medicine to block a protein called IL-17 can help mice with heart problems caused by a virus feel better and live longer.

Methodology

Mice with viral myocarditis were treated with an IL-17 monoclonal antibody, and their survival rates and heart pathology were assessed.

Limitations

The study did not completely reduce VMC symptoms, and the effects of the IL-17 antibody may vary based on dosage and timing.

Participant Demographics

Specific pathogen-free male BALB/c mice, 6 weeks old.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1743-422X-8-17

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication